bstitute	e	1	MAY ?	6 201), 						P	age 1 of 3		
Form PTO-1449 U.S.Department of Commerce (REV. 2-82) Patent AND PARTMENT Office						omme Office	erce		Atty. Docket No. Serial No. AP32738 066876.0103 09/955,877					
NFO	RMAT						STA	TEMENT	Applicant Said I.A. SHALABY et al.					
	BY APPLICANT (Use several sheets if necessary)								Filing Date September 19, 2001		Group 1654			
								U.S. PATEN	T DOCUMENTS					
am.			Docun	nent N	0.			Date	Name	Name Class Subclass		Filing Date ifAppropriate		
nit.	5	8	7	6	7	2	8	03/02/1999	Kass HD et al.			Порторили		
	5	8	7	4	8	0	4	02/23/1999	Rogers SP					
	5	6	4	8	0	8	9	07/15/1997	Shawkat T					
			-	•	-									
								FOREIGN PA	TENT DOCUMENT		1	T		
			Docun	nent N	0.			Date	Country	Class	SubClass	<u>Translato</u> Yes No		
		7	9	3	9	6	4	09/10/1999	Europe (EP)	'				
	_					-				1				
					ED F)		ITC (in alredia a	Author Title Date Doubleant D	ges Ets)	<u></u>	1		
		Hai	vard	School	ol of	Public	Heal	th Jan 2004, <h< td=""><td>Author, Title Date, Pertinent Pattp://www.researchmatters.harvard</td><td>l.edu/story</td><td>php?article</td><td>e_id=673></td></h<>	Author, Title Date, Pertinent Pattp://www.researchmatters.harvard	l.edu/story	php?article	e_id=673>		
	<u> </u>			'										
		Buckwold, Beer, Donis, 2003 "Bovine viral diarrhea as a surrogate model of hepatitis C virus for the evaluation anti-viral agents" Antiviral Research Vol 60(1):1-15;							evaluation of					
/			i-vira	Ŭ		Cost of Developing a New Drug Increases to About \$1.7 Billion By PETER LANDERS, Wall Street Journal December 8, 2003 http://online.wsj.com/article/0,SB107083909136415400-email,00.html								
		Cos	st of I	Devel	oping	a Nev <a drugs<="" href="http://</td><td>w Dra
//onli</td><td>ig Increases to A
ne.wsj.com/artic</td><td>cle/0,,SB107083909136415400-er</td><td>nail,00.htn</td><td>nl></td><td></td></tr><tr><td>/</td><td></td><td>Cos
Dec</td><td>st of I</td><td>Develor 8, 2</td><td>2003</td><td><http:/</td><td>//onli</td><td>ne.wsj.com/artio</td><td>r HIV Infection" lett="" med="" td=""><td>nail,00.htn</td><td>nl></td><td></td>	nail,00.htn	nl>						
		Cos Dec	st of I cembe	Develor 8, 2	2003 M, ed	<http: <="" td=""><td>//onli</td><td>ne.wsj.com/artio</td><td>cle/0,,SB107083909136415400-er</td><td>nail,00.htn</td><td>nl></td><td></td></http:>	//onli	ne.wsj.com/artio	cle/0,,SB107083909136415400-er	nail,00.htn	nl>			
		Cos Dec Ab	st of I cember ramov	Develor 8, 2 wicz I	2003 · M, ed	<a drugs<="" href="http://www.ht</td><td>//onlin</td><td>ne.wsj.com/articide (Fuzeon) fo
lica Acta, 283(1</td><td>r HIV Infection" lett="" med="" td=""><td>rher. 2003</td><td>nl> 3 Jun 23; 450</td><td>(1159): 49-50</td>	rher. 2003	nl> 3 Jun 23; 450	(1159): 49-50					

Examiner

Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

	/	' O'	. .	•	ָר כ	છું
Substitute	(-	MAY	Ź	6	2004	8

Form PTO-1449	U. Department itent and Manual	Commerce
REV. 2-82) Pa	itent and Prepare	rk Office

Atty. Docket No. AP32738 066876.0103

Applicant

Serial No. 09/955,877

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Said I.A. SHALABY et al.

Filing Date Group
September 19, 2001 1654

	•
	Yokozawa, et al., J. Traditional Medicine, 15(1):45-51 (1998)
A	Alter, M.J., Hepatology, 26(1):62S-65S (1997)
•	Alam, et al., Phytotherapy Research, 10(1):58-61 (1996);
	D.S. Chen, J. Formos. Med. Assoc., 95(1):6-12 (1996);
	Detre, et al., Viral Hepatitis Rev., 2:219-228 (1996);
	D.C. Dale and D.D. Federman, eds., Sci. Amer. Medicine, New York, 4(8):1-10 (1996);
	Hibbs, et al., J. Infect. Dis. 168:789-790 (1993);
	Lok, et al., Gastroenterology, 105(6):1833-1838 (1993);
	Flint SJ et al., Principles of Virology: Molecular Biology, Pathogenesis, and Control, ASM Press, Washington DC, 1990, p.691;
	Medicinal Plants of North Africa, Loutfy Boulos, Reference Publications, Inc., pp.150-51 (1983);
	Medicinal Plants of North Africa, pp. 74-75, 92-93 (1983);
	Bergmeyer and Horder, Clinica Chemica Acta 105:147f-154f (1980);
/	Encyclopedia of Common Natural Ingredients, Used in Food, Drugs, and Cosmetics, John Wiley & Sons, New York p.169 (1980);
	International Federation of Clinical Chemistry, Scientific Committee, J. Clin. Chem. Clin. Biochem., 18:521-534 (1980);

NY02:47<u>2768</u>.1

Examiner Date Considered 10/01/04

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

ubstitute		MAY 2 6 2004		Page 3 of 3			
Form PTO- (REV. 2-82)	1449 l Pat	Department of Commerce	Atty. Docket No. AP32738 066876.0103	Serial No. 09/955,877			
		ION DISCLOSURE STATEMENT BY APPLICANT	Applicant Said I.A. SHALABY et al.				
,	(Use	several sheets if necessary)	Filing Date September 19, 2001	Group 1654			
		<u>.</u>					
2		Bergmeyer H. U. Methods of Enzymatic Anal	ysis. Verlag Chemic, (1978), pp. 130	-135;			
21		Babbar, et al., Ind. J. Exp. Biol., 8:304-312 (19	970);				
0		Linus Pauling, General Chemistry, New York	, Dover Publications, Inc., 1970, p 74	14.			
				,			
	-						
	_		. •				
		· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·			
		,					
	1	1					
Y02:47276	58.1						
xaminer	al	week Teel Date	e Considered /0 /01/0 4				

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.